

Sodium-Glucose Co-transporter-2 (SGLT2) Inhibitor Step Therapy

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Brenzavvy (bexagliflozin)	May be subject to quantity limit
Invokamet (canagliflozin/metformin)	
Invokamet XR (canagliflozin/metformin)	
Invokana (canagliflozin)	
Jardiance (empagliflozin)	
Farxiga (dapagliflozin)	
Segluromet (ertugliflozin/metformin)	
Steglatro (ertugliflozin)	
Synjardy (empagliflozin/metformin)	
Synjardy XR (empagliflozin/metformin extended-release)	
Xigduo XR (dapagliflozin/metformin extended-release)	

APPROVAL CRITERIA

Requests for Farxiga (dapagliflozin), Jardiance (empagliflozin), Synjardy (empagliflozin/metformin), Synjardy XR (empagliflozin/metformin extended-release) or Xigduo XR (dapagliflozin/metformin extended-release) may be approved when the following criteria are met:

- I. Individual has had a trial and inadequate response or intolerance to metformin (AACE 2023). Medication samples/coupons/discount cards are excluded from consideration as a trial; **OR**
 - II. Individual has a contraindication to metformin therapy;
- OR**
- III. Farxiga (dapagliflozin) or Jardiance (empagliflozin) may be approved if individual has type 2 diabetes and a history of atherosclerotic cardiovascular disease (ASCVD) including one or more of the following:
 - a. Acute coronary syndrome;
 - b. Coronary artery disease (CAD);
 - c. History of myocardial infarction (MI);
 - d. Stable or unstable angina;

- e. Stroke;
- f. Transient ischemic attack (TIA);
- g. Peripheral arterial disease (PAD);

OR

- IV. Farxiga (dapagliflozin) may be approved for an individual with New York Heart Association (NYHA) class II, III or IV heart failure symptoms when the following criteria are met:
 - A. Individual has an ejection fraction of 40% or less; **AND**
 - B. Individual will be taking Farxiga (dapagliflozin) in combination with a beta blocker (bisoprolol, carvedilol, metoprolol succinate) **AND** an angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor blocker (ARB) or Entresto (sacubitril/valsartan) unless contraindicated or not tolerated (McMurray 2019);

OR

 - C. Individual has an ejection fraction of greater than 40%;
- IV. Farxiga (dapagliflozin) may be approved for an individual with chronic kidney disease at risk for progression when the following criterion is met (Heerspink 2020; KDIGO 2020):
 - A. Individual will be taking Farxiga (dapagliflozin) in combination with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) unless contraindicated or not tolerated;

OR

- V. Jardiance (empagliflozin) may be approved for an individual with New York Heart Association (NYHA) class II, III or IV heart failure symptoms when the following criteria are met:
 - A. Individual has an ejection fraction of 40% or less; **AND**
 - B. Individual will be taking Jardiance (empagliflozin) in combination with a beta blocker (bisoprolol, carvedilol, metoprolol succinate) **AND** an angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor blocker (ARB) or Entresto (sacubitril/valsartan) unless contraindicated or not tolerated (Packer 2020);

OR

 - C. Individual has an ejection fraction of greater than 40%.

Requests for Brenzavvy (bexagliflozin), Invokamet (canagliflozin/metformin), Invokamet XR (canagliflozin/metformin), Invokana (canagliflozin), Segluromet (ertugliflozin/metformin), Steglatro (ertugliflozin), may be approved when the following criteria are met:

- I. Documentation is provided that individual has had a trial and inadequate response or intolerance to metformin (AACE/ACE 2023). Medication samples/coupons/discount cards are excluded from consideration as a trial; **OR**
 - II. Individual has a contraindication to metformin therapy;
- AND**
- III. Individual has had a trial and inadequate response to A. and B. Medication samples/coupons/discount cards are excluded from consideration as a trial
 - A. Jardiance (empagliflozin) or Synjardy (empagliflozin/metformin) or Synjardy XR (empagliflozin/metformin extended release);

AND

B. Farxiga (dapagliflozin) or Xigduo XR (dapagliflozin/metformin extended-release);

OR

- IV. Invokana (canagliflozin) may be approved for an individual with type 2 diabetes and diabetic nephropathy when the following criteria are met (Perkovic 2019):
- A. If initiating therapy, individual has albuminuria greater than 300 mg/day; **AND**
 - B. Individual will be taking Invokana (canagliflozin) in combination with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) unless contraindicated or not tolerated; **AND**
 - C. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to Farxiga (dapagliflozin).

A SGLT2 inhibitor may not be approved for any of the following:

- I. Individual is requesting Brenzavvy (bexagliflozin), Invokana (canagliflozin) or Invokamet/XR (canagliflozin/metformin/extended-release), Segluromet (ertugliflozin/metformin), or Steglatro (ertugliflozin) and has a risk factor for lower limb amputation (including but not limited to history of prior amputation, peripheral vascular disease, neuropathy or diabetic foot ulcers); **OR**
- II. Individual is on dialysis; **OR**
- III. Individual is requesting Jardiance (empagliflozin), Farxiga (dapagliflozin), Invokana (canagliflozin), Steglatro (ertugliflozin) or Brenzavvy (bexagliflozin) with an eGFR less than 20 mL/min/1.73 m² (unless individual is stabilized on the requested agent and using it to treat chronic kidney disease) (KDIGO 2022); **OR**
- IV. Individual is requesting Invokamet (canagliflozin/metformin), Invokamet XR (canagliflozin/metformin), Segluromet (ertugliflozin/metformin), Synjardy (empagliflozin/metformin), Synjardy XR (empagliflozin/metformin extended release) or Xigduo XR (dapagliflozin/metformin extended-release) with an eGFR less than 45 mL/min/1.73m²; **OR**
- V. Individual is requesting for the treatment of type 1 diabetes mellitus; **OR**
- VI. Individual is requesting for weight loss or the treatment of obesity alone.

NOTE:

Invokamet/XR, Segluromet, Synjardy/XR and Xigduo XR have a black box warning for lactic acidosis as they contain metformin. Post-marketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension and resistant bradyarrhythmias. Risk factors include renal impairment, concomitant use of certain agents, age > 65 years, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake and hepatic impairment. If lactic acidosis is suspected, discontinue the metformin-containing agent and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended.

Key References:

- 1. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. *N Engl J Med.* 2021 Oct 14;385(16):1451-1461.

2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: May 10, 2023.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med*. 2020 Oct 8;383(15):1436-1446.
5. Heidenreich P, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. *J Am Coll Cardiol*. 2022 May, 79 (17) e263–e421.
6. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. *Kidney Int*. 2022;102(5S):S1–S127. Available at: <https://kdigo.org/wp-content/uploads/2022/10/KDIGO-2022-Clinical-Practice-Guideline-for-Diabetes-Management-in-CKD.pdf>. Accessed: April 1, 2023.
7. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc. Updated periodically.
8. McMurray JJV, Solomon SD, Inzucchi SE, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med*. 2019 Nov 21;381(21):1995-2008.
9. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *N Engl J Med*. 2020 Oct 8;383(15):1413-1424.
10. Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *N Engl J Med*. 2019 Apr 14.
11. Samson SL, Vellanki P, Blonde L, et. al. American Association of Clinical Endocrinologists (AACE) Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update. *Endocrine Practice*. 2023;29:305-340.
12. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Last updated: November 14, 2017. Available at <https://www.fda.gov/Drugs/DrugSafety/ucm493244.htm>. Accessed: May 9, 2023.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.